(CercleFinance.com) – The Spanish pharmaceutical company Almirall reported lower results for the first half on Monday and at the same time confirmed its objectives for the full year.
The Barcelona group announced this morning that it had generated operating profit (Ebitda) of 107.6 million euros in the first six months of the year, a figure down 21.2% year on year. ‘other.
In a press release, Almirall recalls that its performance in the first half of 2021 had been boosted by proceeds from disposals, but also by the finalization of payments made by its partner AstraZeneca.
The company also points out that its selling, general and administrative (SG&A) costs increased by 9% to 210 million euros over the half-year due to the intensification of research and development (R&D) expenditure and its recent product launches.
At 67.7%, the basic gross margin (‘core’) is in line with the forecasts established for 2022.
Core net sales reached €436.6 million, up 5.1% year-on-year due to the group’s solid performance in the field of dermatology, its new core business.
All these figures were received without much enthusiasm on Monday at the Madrid Stock Exchange, where the Almirall title yielded more than 3% at midday.
Copyright (c) 2022 CercleFinance.com. All rights reserved.